Director?s Overview and Six Essential Characteristics ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) brings together 135 Members from 23 Departments in the City of Hope National Medical Center and the Beckman Research Institute of City of Hope. The Center receives $16,688,443 (Direct) in peer-reviewed funding from the NCI, $15,062,557 (Direct) from other peer- reviewed sources, and $31,637,093 from non-peer-reviewed sources, for a total of $63,388,093 (Direct) in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Fifty-three new faculty have been recruited during the most recent funding period, including 31 clinical investigators, and 23 basic and population research scientists. The Cancer Center has five Programs: Molecular and Cellular Biology of Cancer (MCBC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). In addition, the COHCCC supports nine Shared Resources: Analytical Cytometry, Analytical Pharmacology, Integrative Genomics & Bioinformatics, Multi-omics Mass Spectrometry & Biomarker Discovery, Pathology Research Services, Small Animal Studies, Drug Discovery & Structural Biology, Biostatistics & Mathematical Oncology, and GMP Manufacturing. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that will aid people with cancer, as well as individuals at risk for malignancy. Our research is aligned to reduce the incidence of cancer in the unique populations we serve within our Catchment Area, through investigating 1) biologically aggressive cancers that impact diverse populations; 2) viral-related cancers, including hepatocellular carcinoma and HPV and HIV-related malignancies; 3) the impact of pollution on cancer incidence, with a focus on breast and lung cancers; and 4) cancers of aging in Asian- and Latino-Americans. In addition, the COHCCC is committed to developing the next generation of leaders and practitioners in clinical and translational cancer-related research through robust training initiatives that begin at K-12 outreach and continue through junior faculty development. Finally, overall organization of the institution and its administrative capabilities in terms of leadership, programmatic alignment, development, and authority have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This application documents that the COHCCC has addressed all of the concerns in the prior review, and that Leadership has built a solid structure for achieving its missions and a stronger more sustainable institution than it has ever been.

Public Health Relevance

The City of Hope Comprehensive Cancer Center provides critical infrastructure and shared resources and fosters collaborations among our basic, population, and clinical investigators to identify new methods for the prevention, diagnosis, treatment, and rehabilitation of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-35
Application #
9491621
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2018-04-20
Budget End
2018-11-30
Support Year
35
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications